Biotech/Pharma Stock Trading Alert for BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX)

BPAX Closes at $2.00, up $0.4250 (26.98%) on 10,565,686 shares

Point Roberts, WA - December 28, 2010 (Investorideas.com Newswire) - InvestorIdeas.com, a leader in sector research for investors including biotech stocks, issues a trading alert for BioSante Pharmaceuticals, Inc . (NASDAQ:BPAX). The stock closed at $2.00, up $0.4250 (26.98%) on 10,565,686 shares. The stock was down $0.25 in after hours trading.
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) Recent News and Commentary:
BioSante Pharmaceuticals to Raise $18 Million in Registered Direct Offering
LINCOLNSHIRE , Ill. -- BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that it has received commitments from several institutional investors to purchase $18 million of securities in a registered direct offering. BioSante expects to receive net proceeds of approximately $16.9 million after deducting placement agent fees and other offering expenses. BioSante has entered into securities purchase agreements with these investors pursuant to which BioSante has agreed to sell an aggregate of approximately 10.6 million shares of its common stock and warrants to purchase up to approximately 5.3 million additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase 0.50 of a share of common stock, will be sold for a purchase price of $1.70, a premium to the closing price on the prior full trading day of Thursday December 23, 2010.
"We are pleased to have a commitment from these new and existing institutional investors," said Stephen M. Simes, BioSante's president and chief executive officer. “This additional funding from these high quality biotechnology institutional investors provides us with a strong cash position as we close out the year, ensuring our ongoing focus on our LibiGel® Phase III clinical study program. Our objective is to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2011. LibiGel remains the lead pharmaceutical product in the U.S. in active development for the treatment of hypoactive sexual desire disorder (HSDD) in menopausal women, and we continue to believe that LibiGel has the potential to be the first product approved by the FDA for this common and unmet medical need.”

The warrants to purchase additional shares will be exercisable at an exercise price of $2.00 per share beginning immediately and will expire five years from the date that the warrants are issued. All of the securities were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used for general corporate purposes, including continuing to fund BioSante's LibiGel Phase III clinical study program, as well as to seek opportunities for its GVAX cancer vaccines and other technologies. The offering is expected to be consummated by December 30, 2010, subject to customary closing conditions.
Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (NASDAQ:RODM - News), acted as the exclusive placement agent for the transaction. Roth Capital Partners, LLC, JMP Securities LLC, Oppenheimer & Co. Inc. and Trout Capital, LLC acted as financial advisors.
A shelf registration statement relating to the shares of common stock and warrants issued in the offering (and the shares of common stock issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the “SEC”) and has been declared effective. A prospectus supplement relating to the offering will be filed by BioSante with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from BioSante by contacting BioSante Pharmaceuticals, Inc., 111 Barclay Boulevard, Lincolnshire, Illinois 60069. Copies of the final prospectus supplement and accompanying prospectus relating to the offering also may be obtained from Rodman & Renshaw, LLC, 1251 Avenue of the Americas 20th Floor, New York, NY 10020 or by calling (212) 356-0549. This announcement is neither an offer to sell nor a solicitation of an offer to buy any shares of common stock or warrants of BioSante. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
For Investors: The Trout Group LLC
Tricia Swanson (646) 378-2953
tswanson@troutgroup.com
Or For Media:
McKinney/Chicago
Alan Zachary (312) 944-6784 ext. 316
azachary@mckinneychicago.com
Other news/commentary at Seeking Alpha : Is BioSante Pharmaceuticals Next in Line to Receive Institutional Praise?
http://seekingalpha.com/article/243652-is-biosante-pharmaceuticals-next-in-line-to-receive-institutional-praise?source=yahoo
Visit the BPAX showcase profile at Investorideas.com
http://www.investorideas.com/CO/BPAX/
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About our Biotech investor portal:
BiotechIndustryStocks.com Portal is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: Disclaimer: The following news/content is paid for as part of the BPAX showcase program (three thousand per month November 2010 ) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer:http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) to Raise $18 Million in Registered Direct Offering

LINCOLNSHIRE, Ill. - December 28, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it has received commitments from several institutional investors to purchase $18 million of securities in a registered direct offering. BioSante expects to receive net proceeds of approximately $16.9 million after deducting placement agent fees and other offering expenses. BioSante has entered into securities purchase agreements with these investors pursuant to which BioSante has agreed to sell an aggregate of approximately 10.6 million shares of its common stock and warrants to purchase up to approximately 5.3 million additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase 0.50 of a share of common stock, will be sold for a purchase price of $1.70, a premium to the closing price on the prior full trading day of Thursday December 23, 2010.

"We are pleased to have a commitment from these new and existing institutional investors," said Stephen M. Simes, BioSante's president and chief executive officer. �This additional funding from these high quality biotechnology institutional investors provides us with a strong cash position as we close out the year, ensuring our ongoing focus on our LibiGel� Phase III clinical study program. Our objective is to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2011. LibiGel remains the lead pharmaceutical product in the U.S. in active development for the treatment of hypoactive sexual desire disorder (HSDD) in menopausal women, and we continue to believe that LibiGel has the potential to be the first product approved by the FDA for this common and unmet medical need."
The warrants to purchase additional shares will be exercisable at an exercise price of $2.00 per share beginning immediately and will expire five years from the date that the warrants are issued. All of the securities were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used for general corporate purposes, including continuing to fund BioSante's LibiGel Phase III clinical study program, as well as to seek opportunities for its GVAX cancer vaccines and other technologies. The offering is expected to be consummated by December 30, 2010, subject to customary closing conditions.
Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (NASDAQ:RODM - News), acted as the exclusive placement agent for the transaction. Roth Capital Partners, LLC, JMP Securities LLC, Oppenheimer & Co. Inc. and Trout Capital, LLC acted as financial advisors.
A shelf registration statement relating to the shares of common stock and warrants issued in the offering (and the shares of common stock issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the �SEC") and has been declared effective. A prospectus supplement relating to the offering will be filed by BioSante with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from BioSante by contacting BioSante Pharmaceuticals, Inc., 111 Barclay Boulevard, Lincolnshire, Illinois 60069. Copies of the final prospectus supplement and accompanying prospectus relating to the offering also may be obtained from Rodman & Renshaw, LLC, 1251 Avenue of the Americas 20th Floor, New York, NY 10020 or by calling (212) 356-0549. This announcement is neither an offer to sell nor a solicitation of an offer to buy any shares of common stock or warrants of BioSante. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as �will,� �potential,� �could,� �can,� �believe,� �intends,� �continue,� �plans,� �expects,� �anticipates,� �estimates,� �may,� other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, please contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Biotech Stocks: High Volume Traders; (OTCBB: UVFT), (NASDAQ:AMGN), (OTCBB: GNTA), (NASDAQ:BCRX)

Point Roberts, WA – December 15, 2010 (Investorideas.com Newswire) - InvestorIdeas.com, a
leader in sector research for investors including biotech and pharma stocks , reports on recent
Volume Leading Biotech/ Pharma Stocks news and trading for December 15th for NASDAQ and
microcap stocks.

Biotech stocks in this trading alert include UV Flu Technologies, Inc., (OTCBB: UVFT), Amgen
Inc. (NASDAQ:AMGN), Genta Inc. (OTCBB: GNTA), and BioCryst Pharmaceuticals, Inc.
(NASDAQ:BCRX).

Biotech Sector Snapshot: (Trading at time or release)

UV Flu Technologies, Inc., (OTCBB: UVFT), trading at $ 0.1090, up 0.0090 (9.00%) on over 1.5
Million shares in Volume
Amgen Inc. (NASDAQ:AMGN) trading at $56.20
Genta Inc. (OTCBB: GNTA), trading at $0.0497, up 0.0181 (57.28%) on over 22 Million Shares in
Volume
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) trading at $5.23, up 0.10 (1.75%)

Biotech Stocks News and Profiles-

UV Flu Technologies, Inc., (OTCBB: UVFT) Recent News:

UV Flu Technologies (OTCBB: UVFT) to Finalize Acquisition of Leading Industrial
Grade Air Purification Manufacturer

“CENTERVILLE, MA – December 15, 2010 (Investorideas.com Newswire) - UV Flu
Technologies, Inc. (OTCBB: UVFT) (the "Company"), is pleased to announce that it is moving
forward with plans to acquire a renowned US manufacturer of high quality air purification
equipment designed for industrial applications including specialization in the medical and
hospitality marketplace.

The final milestone prior to the close of the agreement was the completion of a financial audit,
which was successfully concluded last week. A tentative closing date has been targeted for on or
around December 30, 2010.

The agreement includes a patented, trademarked product line, with dozens of national
distributors and representatives, an extensive customer list, inventory, and all associated
manufacturing equipment. The company's sales include an installed base of several thousand
units in over 1000 unique facilities nationwide, including over 400 hospitals.”
Full Article: http://www.investorideas.com/CO/UVFT/news/12151.asp
Website: http://www.uvflutech.com/

Genta Inc. (OTCBB: GNTA) Recent News:

Genta Completes $5 Million Financing

“BERKELEY HEIGHTS, N.J, Genta Incorporated announced today that the Company has
entered into definitive agreements with institutional investors that released $5 million in gross
proceeds from a control account that had been established pursuant to the issuance of
Convertible Notes in March 2010. The funds had been subject to certain restrictions and security
interests, which have been released with the new agreements.

Proceeds of this transaction will be used as follows:

to determine survival results from Genta’s completed Phase 3 trial of Genasense® (oblimersen
sodium) Injection plus chemotherapy as first-line treatment of patients with advanced melanoma
(known as AGENDA). Followup from AGENDA will complete in the 1st-quarter 2011;

to complete Phase 2 and initiate a Phase 3 trial with tesetaxel, the leading oral taxane in clinical
development; and

to select a lead oral gallium-containing compound that will advance to clinical trials for treatment
of diseases associated bone loss.”
Full News at: http://finance.yahoo.com/news/Genta-Completes-5-Million-bw-
244255153.html?x=0&.v=1

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Recent News:

BioCryst Reports New Data from Its Phase 2 Forodesine Study in Patients
with Chronic Lymphocytic Leukemia at the 52nd Annual American Society of
Hematology Meeting

“RESEARCH TRIANGLE PARK, N.C,BioCryst Pharmaceuticals, Inc. today announced the
presentation of new data that confirms forodesine’s clinical activity in the treatment of chronic
lymphocytic leukemia (CLL) at the 52nd Annual American Society of Hematology (ASH) Meeting
& Exposition being held in Orlando, Florida.

In this Phase 2, open-label, single-arm, multi-center study, forodesine was administered orally
at 200 mg twice-daily for 28-day cycles in previously treated CLL patients. The primary endpoint
of the study was overall response rate. An analysis conducted after all patients were followed
through ≥6 months showed that six of 23 response-evaluable patients demonstrated a partial
response to forodesine, resulting in a response rate of 26 percent. Forodesine 200 mg orally-
administered twice-daily was generally safe and well-tolerated in this study. The pattern,
frequencies and severity distribution of adverse events were generally consistent with CLL-
associated poor bone marrow function and immunodeficiency, prior therapies and co-morbidities.”
Full News at: http://finance.yahoo.com/news/BioCryst-Reports-New-Data-bw-
3582084115.html?x=0&.v=1

Amgen Inc. (NASDAQ:AMGN) Recent News:

XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in
Men With Prostate Cancer

Pivotal Phase 3 '147 Study Meets Primary Endpoint
First Bone-Targeted Therapy to Delay the Onset of Bone Metastases in Patients with Prostate
Cancer
“THOUSAND OAKS, Calif., Dec. 13, 3010 Amgen today announced top-line results from a Phase
3 trial evaluating XGEVA™ (denosumab) versus placebo in 1,432 men with castrate-resistant
prostate cancer. The trial, known as the '147 study, demonstrated that XGEVA significantly
improved median bone metastasis-free survival by 4.2 months (HR=0.85, 95 percent CI 0.73-
0.98, p=0.03) compared to placebo (primary endpoint), and significantly improved time to first
occurrence of bone metastases (secondary endpoint). Overall survival was similar between the
XGEVA and placebo groups (secondary endpoint).

Overall rates of adverse events and serious adverse events were generally similar between
XGEVA and placebo, with hypocalcemia and osteonecrosis of the jaw (ONJ) observed at
increased frequencies in the XGEVA arm. The yearly rate of ONJ in the XGEVA-treated group
was similar to what has been observed in prior XGEVA trials.”
Full News at: http://finance.yahoo.com/news/XGEVA-Denosumab-Significantly-prnews-
2515773001.html?x=0&.v=1

About InvestorIdeas.com:

InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector
investing, covering leading industry sectors including mining and gold stocks, in addition to global markets
including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive
stock directories in each sector and sector specific newswires.

Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/
Stock_List.asp

About our Biotech investor portal:

BiotechIndustryStocks.com Portal is a global meeting place for investors and industry following the sector,
within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio,
research reports and our stock directories.

Showcase Biotech Stock UV Flu Technologies, Inc. (UVFT.OB):
UV Flu Technologies, Inc. (OTCBB: UVFT) is an innovative developer, manufacturer and
distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality
("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-
intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration
to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH
UV-400 is a Class II medical device and is available
Visit the showcase page on Investorideas.com For UV Flu Technologies, Inc., (OTCBB:
UVFT)
http://www.investorideas.com/CO/UVFT/

Contact UV Flu Technologies, Inc.

John J. Lennon, President & CEO

Contact:
Investor Information:

Geaux IR Services, Inc.

Toll-Free: 1-888-355-8838

investors@uvflutech.com

SOURCE: UV Flu Technologies, Inc.

Get added to the company’s news alerts:
http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer: Disclaimer: The following news/content is paid for as part of the UVFT showcase program (two thousand

per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations,
but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured
companies, news submissions and online advertising.
.Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

C Van Zant: 800-665-0411 - cvanzant@investorideas.com

Source - Investorideas.com

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) to Finalize Acquisition of Leading Industrial Grade Air Purification Manufacturer

CENTERVILLE, MA � December 15, 2010 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company"), is pleased to announce that it is moving forward with plans to acquire a renowned US manufacturer of high quality air purification equipment designed for industrial applications including specialization in the medical and hospitality marketplace.

The final milestone prior to the close of the agreement was the completion of a financial audit, which was successfully concluded last week. A tentative closing date has been targeted for on or around December 30, 2010.
The agreement includes a patented, trademarked product line, with dozens of national distributors and representatives, an extensive customer list, inventory, and all associated manufacturing equipment. The company's sales include an installed base of several thousand units in over 1000 unique facilities nationwide, including over 400 hospitals.
"We are thrilled that the acquisition could close by year-end," said Jack Lennon, President of UV Flu Technologies. "With the acquisition of this Company, our product line will be complemented at the industrial level, while the introduction of our residential product will round-out the consumer end of the retail spectrum. Our current flagship product, the UV-400, can protect indoor spaces of up to 600-900 sq. ft., while the product line we will offer as a result of the new acquisition protects environments regularly ranging from 1000-5000 sq. ft. Additionally, our soon-to-be-introduced residential product will easily protect spaces under 600 sq. ft., providing us with full coverage for most every indoor scenario. We have extensively studied the test results and are satisfied that the HEPA based technology we are acquiring captures in excess of 99.97% of the particulates passing through it, is the finest in the industry, and an excellent fit to our long term goals," said Mr. Lennon.
"Our new acquisition will be operated as a subsidiary of UV Flu Technologies, and will provide a US manufacturing base to aid in the pursuit of government and DoD contract opportunities. We anticipate this added market segment will also lead to additional jobs and overall growth for the Company," said Mr. Lennon. "The enhanced product line will make us increasingly attractive to large US distributors, and increase our visibility within the hospital, hotel and casino marketplace. Upon the close of the transaction we will immediately reveal the identity of the acquisition and introduce our distributors to the entire product line, both domestically, as well as internationally. We believe the synergies will be extraordinary and hope to significantly increase our revenue estimates for 2011 as a result. Once our residential model is introduced to the lineup in 2011 we are highly optimistic for increased traction across the entire segment. We are very encouraged by the prospects and look forward to offering a full line of products that really work -- and all of which offer verified and laboratory proven test data for every application."
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/
Request info:
http://www.investorideas.com/Resources/Newsletter.asp

Investor Video; BioSante (NASDAQ: BPAX) CEO Discusses BioSante Portfolio of Cancer Vaccines

CEO reports, “There are fifteen BioSante cancer vaccine Phase I and Phase II studies
ongoing in different cancers.”

Point Roberts, WA, LINCOLNSHIRE, Ill –December 2, 2010 (Investorideas.com Newswire)
Investorideas.com, an investor research portal specialized in sector investing including biotech
and pharma stocks, releases a video presentation featuring BioSante Pharmaceuticals, Inc.
(NASDAQ: BPAX) for interested investors.

The video, featuring Stephen M. Simes, President and CEO, was recorded during “Cancer
Immunotherapy: A Long Awaited Reality”, a conference hosted by BioBusiness.TV and MD
Becker Partners on October 21st, 2010, at the New York Academy of Medicine. Mr. Simes
discusses the GVAX wide portfolio of cancer vaccines.

Mr. Simes reports, “There are fifteen BioSante cancer vaccine Phase I and Phase II studies
ongoing in different cancers.”

Watch BioSante’s segment on Cancer Vaccines for the Cancer Immunotherapy
Conference the following link is provided: http://www.biobusiness.tv/report-on-location/
biosante-presentation-at-cancer-immunotherapy-conference-1548/

Highlights from the Cancer Vaccines Product Page:

Read the Full info at: http://www.biosantepharma.com/Cancer-Vaccines.php

BioSante Pharmaceuticals Inc. is developing a pipeline of Immunotherapies (cancer vaccines).
BioSante’s cancer vaccines use cell lines that are genetically modified to secrete granulocyte-
macrophage colony-stimulating factor (GM-CSF), an immunostimulant. The cells then are
irradiated to prevent further cell division; however the cells remain metabolically active.

Currently, BioSante’s Cancer Vaccines are in various Phase I and Phase II cancer clinical
trials and may represent the widest portfolio (cancer types) of cancer vaccines in development.
Studies are conducted primarily at Johns Hopkins Cancer Center and are sponsored/funded
by The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, various philanthropies,
foundations and the National Cancer Institute

Cancer Types Being Studied:
•
•Leukemia
◦Chronic Myeloid Leukemia (CML)
◦Acute Myeloid Leukemia (AML)
•Pancreatic Cancer
•Breast Cancer
•Multiple Myeloma
•Melanoma
•Colorectal
Prostate Cancer

Chronic Myeloid Leukemia (CML) — Results of a Phase II clinical trial
Of 19 patients treated with GVAX CML, 7 had complete remission.

•Gleevec was taken for at least one year (range 13-53 months) pre-vaccine and then GVAX CML

was administered while the patients remained on a stable dose of Gleevec.
◦19 patients enrolled (median of 72 months of follow-up)
◦13 patients (8 of whom had increasing disease burden before vaccination): the number of
remaining cancer cells declined
◦12 patients reached their lowest levels of residual cancer cells to date following vaccination
◦7 patients had complete remission
"We want to get rid of every last cancer cell in the body, and using cancer vaccines may be a
good way to mop up residual disease," said lead investigator Hyam Levitsky, M.D., professor
of oncology, medicine and urology at the Johns Hopkins Kimmel Cancer Center in Baltimore,
Maryland.

Acute Myeloid Leukemia (AML) — Results of Phase II
Patients treated with GVAX had both a relapse-free survival and overall survival rate
improvement of approximately 30% compared with the non-GVAX-treated subjects.

•GVAX AML was accompanied by immunotherapy-primed lymphocytes after autologous stem cell
transplantation.
◦54 subjects enrolled
◦28 (52%) received a pre-transplantation GVAX AML dose
◦46 (85%) subjects achieved complete remission during the treatment period. Of these patients,
the 3-year relapse-free survival (RFS) rate was:
■47.4% in non-GVAX treated patients
■61.8% in the GVAX-treated group
■Overall survival (OS) rate in all subjects was 57.4%
■Overall survival (OS) rate was 73.4% in the GVAX-treated group
■In summary, patients treated with GVAX had both a relapse-free survival and overall survival
rate improvement of approximately 30% compared with the non-GVAX-treated subjects

Read more on BioSante’s Cancer Vaccines and clinical trial info at: http://
www.biosantepharma.com/Cancer-Vaccines.php

Research more biotech stocks at the Biotech stocks Directory: http://
www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. Investorideas.com is
known for its comprehensive stock directories in each sector and sector specific newswires.

About our Biotech investor portal: www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the
sector, within Investorideas.com. Global visitors use the site daily to research the latest news,
articles, audio, research reports and our stock directories.

If you have any questions regarding information in this press release please contact the company
listed in the press release.
Contact BioSante Pharmaceuticals

For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:

McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

The content from the investor Fact sheet and opinions from http://
www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of
Investorideas.com or related websites.

Disclaimer:
The following news is paid for by BPAX (three thousand per month) Investorideas.com is a
third party publisher of news and research .Our sites do not make recommendations, but offer
information portals to research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell products or securities. This site
is currently compensated by featured companies, news submissions and online advertising.

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks
800 665 0411 cvanzant@investorideas.com

Q&A Interview with Fast Growing Biotech Products Company UV Flu Technologies (OTCBB: UVFT)

December 1, 2010 (Investorideas.com Newswire, www.biotechindustrystocks.com ) - www.InvestorIdeas.com and its leading Biotech investor portal release a Q&A with biotech company UV Flu Technologies, Inc. (OTCBB: UVFT). Mr. John J. Lennon, President & CEO, discusses recent developments with the company's air purifying technology, ViraTech UV-400.

Interview:
Q: Investorideas.com
To give investors an introduction, UV Flu Technologies Inc. (OTCBB: UVFT) develops and manufactures technologies within the Indoor Air Quality (IAQ) industry sector, with your primary product, the ViraTech™ UV-400 model that purifies indoor air by killing bacteria, including superbugs such as NDM-1.
As global awareness increases for the need for better air and water quality technology, your company is aggressively marketing its technology to both consumers and industry. Can you give some hi- lights of what's in the pipeline?
A: Our Company is building a brand. The inadequacy of previous entrants in the air-purifier marketplace makes our job all the more important. Companies in the past, and present, continue to sell millions of air purifiers, with technology that just doesn't work in the residential marketplace. Our products are designed to work with almost no maintenance required. As long as the green light is on, our UV-400 is killing contaminants! We are designing a model specifically for the residential marketplace that we believe will be a category killer! It will have all the killing capabilities of our UV-400, at a lower price point. It will have the capability to kill, and trap, will be the most attractive air purifier in the world, and will have independent, FDA/EPA lab certified test results to support every claim. It will also have 3-4 times the coverage of a typical HEPA based unit, at the same price.
We will also purchase higher volume models to extend our lines on the commercial side.
Q: Investorideas.com
According to your website," Independent EPA and FDA certified laboratory testing confirms the system kills airborne bacteria at rates ranging from 99.2% to more than 99.99% on a first-pass basis. In actual operation multiple passes through the unit will occur, producing average removal rates that far exceed 99.2%." How does this compare to competition in terms of cost and efficiency?
A: Interestingly enough, there are very few units in the world today that actually kill contaminants. Over 95% of air purifiers on the market today capture, but don't kill contaminants. They rely on electrostatic, or HEPA filter technology, which captures, but doesn't kill particulates. All of these products, if filters or plates are not replaced or cleaned on a regular basis, can produce air that is actually dirtier than leaving the unit off. The filters become a “petrie" dish, where bacterial or viral colonies can grow in the filter.
The UV-400 has a kill chamber, which uses Germicidal UV light to kill organic contaminants. Independent lab tests have verified that the killing ability is almost identical, whether it is bacteria, or viruses. The unit can cover a space of up to 7-900 sq ft, while still passing the air 3X per hour. Competing HEPA or electrostatic products can cover 150-200 sq ft, when the filter is clean-less when the filter is dirty. It would typically take 4 HEPA filters to cover the same space. These products typically need $100-150 annually in new filters, as well.
Q: Investorideas.com
The company has completed the design of its second product, a smaller, lower cost version of the ViraTech™ UV-400. Can you give us some insight into the markets and applications for it?
A: One residential electrostatic air purifier product sold 3 million units at $400 apiece, before it was pulled from the market, due to its inability to clean the air. We think there is an international market potential for our product of several hundred thousand units per year. The market would be geared to the market for bedrooms, apartments, hotel room, and small offices, where price points, and space coverage requirements are lower.
Q: Investorideas.com
According to a recent report by Global Industry Analysts, Inc., demand for air filters in developing countries will outpace growth in mature markets such as US, European, and Japan. By 2015, China will supplant Japan to become the second largest market for air filter equipment behind United States. What are the company's plans to participate in the global market?
A: The Company already has the international markets in its sights. Air quality in developing markets, including China, is considerably worse than in this country. The Company has begun shipping units to Europe, which suffers from epidemic rates of HAI's, or hospital associated infections, like MRSA, and plans on having distribution to China by mid-year 2011.
About UV Flu Technologies, Inc. (OTCBB: UVFT).
UV Flu Technologies, Inc. (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available.
Investors can view the full company profile for UV Flu Technologies, Inc. (UVFT.OB) at: http://www.investorideas.com/CO/UVFT/
Research Report by Michael Williams, Biotech Stock Pick: www.biotechstockpick.com
Find out more about UV Flu Technologies, Inc. (UVFT.OB) at: www.uvflutech.com
Request news and stock alerts from UV Flu Technologies, Inc. (UVFT.OB)
http://www.investorideas.com/Resources/Newsletter.asp
Contact UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
About InvestorIdeas.com :
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal : www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
For Additional Information about Investorideas.com Biotech portals:
800-665-0411

Investor Video; BioSante (NASDAQ: BPAX) Presentation at Cancer Immunotherapy Conference BioSante Pharmaceutical’s President and CEO Discusses BioSante Portfolio of Cancer Vaccines

Point Roberts, WA, LINCOLNSHIRE, Ill - November 30, 2010 (Investorideas.com Newswire) Invest orideas.com, an investor research portal specialized in sector investing including biotech and pharma stocks, features an investor video featuring showcase company BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX).

The video, featuring Stephen M. Simes, President and CEO, was recorded during "Cancer Immunotherapy: A Long Awaited Reality", a conference hosted by BioBusiness.TV and MD Becker Partners on October 21st, 2010, at the New York Academy of Medicine. Mr. Simes discusses the GVAX wide portfolio of cancer vaccines.
Mr. Simes reports, "There are fifteen BioSante cancer vaccine Phase I and Phase II studies ongoing in different cancers."
Watch BioSante's segment on Cancer Vaccines for the Cancer Immunotherapy Conference the following link is provided: http://www.biobusiness.tv/report-on-location/biosante-presentation-at-cancer-immunotherapy-conference-1548/
Highlights from the Cancer Vaccines Product Page:
Read the Full info at: http://www.biosantepharma.com/Cancer-Vaccines.php
BioSante Pharmaceuticals Inc. is developing a pipeline of Immunotherapies (cancer vaccines). BioSante's cancer vaccines use cell lines that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), an immunostimulant. The cells then are irradiated to prevent further cell division; however the cells remain metabolically active.
Currently, BioSante's Cancer Vaccines are in various Phase I and Phase II cancer clinical trials and may represent the widest portfolio (cancer types) of cancer vaccines in development. Studies are conducted primarily at Johns Hopkins Cancer Center and are sponsored/funded by The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, various philanthropies, foundations and the National Cancer Institute
Cancer Types Being Studied:

• Leukemia
• Chronic Myeloid Leukemia (CML)
• Acute Myeloid Leukemia (AML)
• Pancreatic Cancer
• Breast Cancer
• Multiple Myeloma
• Melanoma
• Colorectal
• Prostate Cancer

Chronic Myeloid Leukemia (CML) — Results of a Phase II clinical trial
Of 19 patients treated with GVAX CML, 7 had complete remission.

• Gleevec was taken for at least one year (range 13-53 months) pre-vaccine and then GVAX CML was administered while the patients remained on a stable dose of Gleevec.
• 19 patients enrolled (median of 72 months of follow-up)
• 13 patients (8 of whom had increasing disease burden before vaccination): the number of remaining cancer cells declined
• 12 patients reached their lowest levels of residual cancer cells to date following vaccination
• 7 patients had complete remission

"We want to get rid of every last cancer cell in the body, and using cancer vaccines may be a good way to mop up residual disease," said lead investigator Hyam Levitsky, M.D., professor of oncology, medicine and urology at the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland.
Acute Myeloid Leukemia (AML) — Results of Phase II
Patients treated with GVAX had both a relapse-free survival and overall survival rate improvement of approximately 30% compared with the non-GVAX-treated subjects.

• GVAX AML was accompanied by immunotherapy-primed lymphocytes after autologous stem cell transplantation.
• 54 subjects enrolled
• 28 (52%) received a pre-transplantation GVAX AML dose
• 46 (85%) subjects achieved complete remission during the treatment period. Of these patients, the 3-year relapse-free survival (RFS) rate was:
  • 47.4% in non-GVAX treated patients
  • 61.8% in the GVAX-treated group
  • Overall survival (OS) rate in all subjects was 57.4%
  • Overall survival (OS) rate was 73.4% in the GVAX-treated group
  • In summary, patients treated with GVAX had both a relapse-free survival and overall survival rate improvement of approximately 30% compared with the non-GVAX-treated subjects

Read more on BioSante's Cancer Vaccines and clinical trial info at: http://www.biosantepharma.com/Cancer-Vaccines.php
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal : www.biotechindustrystocks.com
BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
If you have any questions regarding information in this press release please contact the company listed in the press release.
Contact BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
The content from the investor Fact sheet and opinions from http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf are not the opinion of Investorideas.com or related websites.
Disclaimer:
The following news is paid for by BPAX (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com to become a biotech showcase stock or research biotech stocks
800 665 0411 cvanzant@investorideas.com

Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.